Literature DB >> 29500268

Bifidobacterium breve UCC2003 Employs Multiple Transcriptional Regulators To Control Metabolism of Particular Human Milk Oligosaccharides.

Kieran James1,2, Mary O'Connell Motherway2, Christophe Penno2, Rebecca Louise O'Brien1,2, Douwe van Sinderen3,2.   

Abstract

Bifidobacterial carbohydrate metabolism has been studied in considerable detail for a variety of both plant- and human-derived glycans, particularly involving the bifidobacterial prototype strain Bifidobacterium breve UCC2003. We recently elucidated the metabolic pathways by which the human milk oligosaccharide (HMO) constituents lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and lacto-N-biose (LNB) are utilized by B. breve UCC2003. However, to date, no work has been carried out on the regulatory mechanisms that control the expression of the genetic loci involved in these HMO metabolic pathways. In this study, we describe the characterization of three transcriptional regulators and the corresponding operator and associated (inducible) promoter sequences, with the latter governing the transcription of the genetic elements involved in LN(n)T/LNB metabolism. The activity of these regulators is dependent on the release of specific monosaccharides, which are believed to act as allosteric effectors and which are derived from the corresponding HMOs targeted by the particular locus.IMPORTANCE Human milk oligosaccharides (HMOs) are a key factor in the development of the breastfed-infant microbiota. They function as prebiotics, selecting for a specific range of microbes, including a number of infant-associated species of bifidobacteria, which are thought to provide a range of health benefits to the infant host. While much research has been carried out on elucidating the mechanisms of HMO metabolism in infant-associated bifidobacteria, to date there is very little understanding of the transcriptional regulation of these pathways. This study reveals a multicomponent transcriptional regulation system that controls the recently identified pathways of HMO metabolism in the infant-associated Bifidobacterium breve prototype strain UCC2003. This not only provides insight into the regulatory mechanisms present in other infant-associated bifidobacteria but also provides an example of a network of sequential steps regulating microbial carbohydrate metabolism.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HMO; bifidobacteria; carbohydrate metabolism; prebiotic; probiotic; transcriptional regulation

Mesh:

Substances:

Year:  2018        PMID: 29500268      PMCID: PMC5930313          DOI: 10.1128/AEM.02774-17

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  79 in total

Review 1.  The lac repressor.

Authors:  Mitchell Lewis
Journal:  C R Biol       Date:  2005-06       Impact factor: 1.583

Review 2.  Lactose repressor protein: functional properties and structure.

Authors:  K S Matthews; J C Nichols
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

Review 3.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics.

Authors:  G R Gibson; M B Roberfroid
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

4.  Purification, crystallization and preliminary X-ray analysis of the galacto-N-biose-/lacto-N-biose I-binding protein (GL-BP) of the ABC transporter from Bifidobacterium longum JCM1217.

Authors:  Jun Wada; Ryuichiro Suzuki; Shinya Fushinobu; Motomitsu Kitaoka; Takayoshi Wakagi; Hirofumi Shoun; Hisashi Ashida; Hidehiko Kumagai; Takane Katayama; Kenji Yamamoto
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-10

5.  Selective carbohydrate utilization by lactobacilli and bifidobacteria.

Authors:  D Watson; M O'Connell Motherway; M H C Schoterman; R J Joost van Neerven; A Nauta; D van Sinderen
Journal:  J Appl Microbiol       Date:  2013-01-11       Impact factor: 3.772

6.  Transcription of two adjacent carbohydrate utilization gene clusters in Bifidobacterium breve UCC2003 is controlled by LacI- and repressor open reading frame kinase (ROK)-type regulators.

Authors:  Kerry Joan O'Connell; Mary O'Connell Motherway; Andrea Liedtke; Gerald F Fitzgerald; R Paul Ross; Catherine Stanton; Aldert Zomer; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2014-06       Impact factor: 4.792

7.  Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium.

Authors:  Muireann Egan; Mary O'Connell Motherway; Michelle Kilcoyne; Marian Kane; Lokesh Joshi; Marco Ventura; Douwe van Sinderen
Journal:  BMC Microbiol       Date:  2014-11-25       Impact factor: 3.605

8.  Transcriptional Regulation of Carbohydrate Utilization Pathways in the Bifidobacterium Genus.

Authors:  Matvei S Khoroshkin; Semen A Leyn; Douwe Van Sinderen; Dmitry A Rodionov
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

9.  Global transcriptional landscape and promoter mapping of the gut commensal Bifidobacterium breve UCC2003.

Authors:  Francesca Bottacini; Aldert Zomer; Christian Milani; Chiara Ferrario; Gabriele Andrea Lugli; Muireann Egan; Marco Ventura; Douwe van Sinderen
Journal:  BMC Genomics       Date:  2017-12-28       Impact factor: 3.969

10.  Transposon mutagenesis in Bifidobacterium breve: construction and characterization of a Tn5 transposon mutant library for Bifidobacterium breve UCC2003.

Authors:  Lorena Ruiz; Mary O'Connell Motherway; Noreen Lanigan; Douwe van Sinderen
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more
  9 in total

Review 1.  Building Robust Assemblages of Bacteria in the Human Gut in Early Life.

Authors:  Gerald W Tannock
Journal:  Appl Environ Microbiol       Date:  2021-09-01       Impact factor: 4.792

2.  Maximum depth sequencing reveals an ON/OFF replication slippage switch and apparent in vivo selection for bifidobacterial pilus expression.

Authors:  Christophe Penno; Mary O'Connell Motherway; Yuan Fu; Virag Sharma; Fiona Crispie; Paul D Cotter; Benoit Houeix; Lokesh Joshi; Francesca Bottacini; Aoife O'Dwyer; Gary Loughran; John F Atkins; Douwe van Sinderen
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

3.  Maternal gut microbiota Bifidobacterium promotes placental morphogenesis, nutrient transport and fetal growth in mice.

Authors:  Jorge Lopez-Tello; Zoe Schofield; Amanda N Sferruzzi-Perri; Lindsay J Hall; Raymond Kiu; Matthew J Dalby; Douwe van Sinderen; Gwénaëlle Le Gall
Journal:  Cell Mol Life Sci       Date:  2022-06-28       Impact factor: 9.207

Review 4.  Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents.

Authors:  Anaïs Rousseaux; Carole Brosseau; Sophie Le Gall; Hugues Piloquet; Sébastien Barbarot; Marie Bodinier
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

Review 5.  Human Milk Oligosaccharides and Immune System Development.

Authors:  Julio Plaza-Díaz; Luis Fontana; Angel Gil
Journal:  Nutrients       Date:  2018-08-08       Impact factor: 5.717

Review 6.  Utilization of Host-Derived Glycans by Intestinal Lactobacillus and Bifidobacterium Species.

Authors:  Manuel Zúñiga; Vicente Monedero; María J Yebra
Journal:  Front Microbiol       Date:  2018-08-17       Impact factor: 5.640

7.  Effects of prebiotics on sepsis, necrotizing enterocolitis, mortality, feeding intolerance, time to full enteral feeding, length of hospital stay, and stool frequency in preterm infants: a meta-analysis.

Authors:  Cheng Chi; Nicholas Buys; Cheng Li; Jing Sun; Chenghong Yin
Journal:  Eur J Clin Nutr       Date:  2018-12-19       Impact factor: 4.016

8.  Comprehensive Mining and Characterization of CRISPR-Cas Systems in Bifidobacterium.

Authors:  Meichen Pan; Matthew A Nethery; Claudio Hidalgo-Cantabrana; Rodolphe Barrangou
Journal:  Microorganisms       Date:  2020-05-12

Review 9.  Human Milk Microbiota and Oligosaccharides: A Glimpse into Benefits, Diversity, and Correlations.

Authors:  Carole Ayoub Moubareck
Journal:  Nutrients       Date:  2021-03-29       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.